Cabaser® (cabergoline)
This section provides a summary of the drug information for Cabaser®(cabergoline).
If you have any further questions about your PD medication, or other aspects of your PD treatment, you should discuss these with your doctor or other healthcare professional.
Cabaser® is used to treat the symptoms of Parkinson’s Disease.
It is used as a second line therapy after your Doctor has tried other treatments that have not worked or for people who are already taking other medicines to manage the signs and symptoms of Parkinson's disease.
Cabergoline belongs to a group of medicines called dopamine agonists. The tablets contain the active ingredient Cabergoline which acts in a similar way to a chemical in the body called dopamine.
Pfizer will discontinue the production and distribution of the Cabaser® 4mg tablets from the European Union from 31 October 2008, following a European safety review.
In a letter to UK doctors, the pharmaceutical company said that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that Cabaser and a related drug Dostinex, used to treat hyperprolactinaemia (raised levels of the hormone prolactin in the blood), were associated with the onset of cardiac valve problems known as fibrotic cardiac valvulopathy.
The CHMP had consequently restricted the maximum recommended dose of Cabaser to 3mg a day, with the recommended starting dose of 0.5mg per week and the therapeutic dose of 1mg per week.
Cabaser® and Dostinex® are now contraindicated in people with a history of fibrotic disorders and evidence of cardiac vavulopathy. Anyone taking these medications must undergo echocardiographic monitoring of the heart before treatment and regularly during treatment, with doctors directed to monitor clinical evidence of other fibrotic disorders.
Product information downloads
The information on this pageprintout is a general summary of the Cabaser®medication product.
Please click on the links below to download more detailed information on the specific Cabaser® medication, its handling and use. Links go to the electronic Medicines Compendium (eMC) website.
Further detailed information on the Cabaser® medication, its handling and use can be downloaded via the electronic Medicines Compendium (eMC) website (http://emc.medicines.org.uk/):
Patient Information Leaflets (PIL)
Summary of Product Characteristics (SPC)
Please note that SPCs are designed for healthcare professionals.
Cabaser®(cabergoline) is a trademark of Pharmacia Ltd.